|
|
Background: The safety of blood transfusion can be significantly affected by complex blood group antigens, especially the polymorphic Rh blood group system. This case study is to alert clinicians and laboratory personnel to accurately identify and manage RhD blood groups.
Methods: A Chinese female patient with cervical squamous cell carcinoma underwent surgical treatment; her blood typing identified that she had serological type A and different RhD titers to the anti-D reagent. RHD genetic testing was performed.
Results: After RHD gene sequencing, the patient was confirmed as RhDV Type 1; 1.5 units of type A RhD-negative suspended red blood cells were transfused to the patient, and the hemoglobin level increased from 66 to 73 g/L. No adverse reaction occurred, and the patient recovered well after surgery.
Conclusions: RhD antibody reagents from different manufacturers are required to identify the RhD subtypes and ensure transfusion safety.
DOI: 10.7754/Clin.Lab.2025.250139
|
